L
Eli Lilly and Company
LLY · Healthcare
Q4 FY2025
Earning ended Dec 31, 2025Report generated Mar 10, 2026
Lilly Has Already Won Round One — Round Two Is Oral
The market debate centers on whether tirzepatide justifies a premium multiple, but the question that actually determines the ten-year outcome is whether Lilly's own orforglipron cannibalizes the injectable franchise or unlocks a patient population so much larger that it makes the injection business look like a rounding error — management is betting on the latter, and they're probably right, but getting the transition timing wrong by even two years reshapes the entire return profile.
Flowly Score
Apr 16 Close
+49%$903.43
Fair Value
$1,350.00
65
Strongat $903.43
Business Strength8/10
Tirzepatide's dual-agonist mechanism sits atop a manufacturing moat that took a decade to build and cannot be replicated quickly — ROIC expanding even as the asset base grows is the hallmark of a true compounding machine. The concentration in a single molecular family is a genuine structural risk, but the pipeline breadth across metabolic disease, neurology, and oncology suggests institutional drug-discovery capability rather than one lucky molecule.
Financial Resilience6/10
The balance sheet is intentionally stressed — debt has grown significantly as management bets billions on manufacturing capacity before the revenue fully arrives, and FCF has been suppressed by capex running far above depreciation. The Altman Z score and Piotroski signal underlying creditworthiness, but this is a construction site right now, not a cash fortress, and the thesis depends on that infrastructure filling with paying volume on schedule.
Growth & Trajectory9/10
Few large-cap businesses of this scale have ever printed revenue and earnings growth at this velocity simultaneously — the operating leverage is working exactly as the bull case projected. The runway extends well beyond the current product cycle: Medicare obesity coverage expansion, oral GLP-1 market development, and tirzepatide indication extensions into NASH, sleep apnea, and psychiatric conditions represent multiple compounding layers that aren't yet in the revenue line.
Valuation6/10at $1,008.39
The multiple has already compressed dramatically as earnings caught up to the earlier hype — this is no longer a story priced purely on hope, but on delivered execution — yet the earnings yield remains thin and the neutral DCF barely clears current pricing, leaving little room for error. The FCF yield is deceptive because capex is artificially suppressing the denominator; normalized earning power is substantially higher than the reported figure, which is the real valuation anchor.
Risk4/10
The concentration risk is stark — a safety signal, a manufacturing shortfall, or a superior oral competitor arriving first would each hit with full force on a franchise generating the overwhelming majority of near-term growth. The Inflation Reduction Act creates a structural pricing ceiling that is one-way, and the compounding pharmacy shadow market has already demonstrated willingness to undercut branded pricing at scale, both of which compress the long-run pricing umbrella even if volume holds.
The investment case here is unusual in large-cap pharma: the quality of the business is genuinely exceptional — margins approaching software territory, ROIC expanding into a growing asset base, institutional drug-discovery capability demonstrated across multiple concurrent pipeline successes — but the price reflects much of that quality already. The multiple has compressed meaningfully as earnings have grown into the valuation, which is actually constructive: this is no longer a speculation on scientific promise but a bet on execution of an already-proven franchise. The neutral fair value modestly exceeds current pricing, which means you're paying roughly right for a business that is genuinely above average. Where this business is heading is more interesting than where it currently sits. The obesity and metabolic disease platform is years away from saturation — Medicare coverage access, international market development, and the cascading indication approvals across NASH, sleep apnea, and cardiometabolic disease each represent incremental revenue streams layered onto existing infrastructure. Tirzepatide is revealing itself as a biologic platform rather than a single drug, much the way a cloud computing operating system supports an expanding ecosystem of services. The NVIDIA partnership and direct-to-consumer platform are early signals that management is thinking about defensibility across multiple dimensions simultaneously. The single biggest risk is self-disruption, specifically the oral GLP-1 transition. If orforglipron or a competitor's oral agent achieves comparable efficacy to injectable tirzepatide at a meaningfully lower price point, the billions invested in injectable peptide manufacturing capacity become partially stranded — a real capital impairment hidden inside what looks like forward-thinking investment. Lilly is racing against itself and others simultaneously, and the winner of the oral GLP-1 race rewrites the long-run competitive structure of the entire obesity market.